The end of bacterial resistance.
Patented methylglyoxal disrupts the bacterial cell wall through a multi-site mechanism pathogens cannot route around. No evolutionary resistance observed across two decades.
Clinical-stage pharmaceutical platform
The end of bacterial resistance.
Logix Biosciences develops a patented class of structurally disruptive antimicrobials, engineered to defeat resistant bacteria, act as an effective antiviral, and drive angiogenic tissue repair.
20+ yrs
no observed resistance
One engine, three fronts
20+ yrs
No observed evolutionary resistance
2
Parallel patented assets, botanical + synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
One engine
One molecule. Three therapeutic fronts.
A single patented composition of methylglyoxal, working through one structural mechanism, addresses three of medicine's hardest problems at once.
An effective antiviral.
The same composition acts against enveloped respiratory viruses at the point of entry, before infection can take hold.
An effective angiogenic.
Promotes angiogenesis and accelerates tissue repair, supporting the body and its wound-healing and regenerative pathways.
The platform
Not one molecule. A patented platform.
Two independently patented assets, one botanical and one synthetic, share the same disruptive composition and unlock parallel, expedited routes to patients.
Botanical matrix
Lepto242
Patented Medical Grade Manuka composition, in human use since 1996, qualifying the 505(b)1 botanical FDA pathway.
Synthetic small molecule
Lgx242
Synthetic methylglyoxal derivative built for precision delivery. Qualifies QIDP under the GAIN Act for +5 years exclusivity and Fast Track, plus the LPAD pathway.
Why it matters
A future where infections stay treatable.
Drug-resistant bacteria are among the gravest threats to global health. A composition that pathogens cannot evolve around, paired with antiviral and tissue-healing action, points to a different future for millions of patients.
To usher in the Post-Resistance Era by delivering safe, structurally disruptive antimicrobials to millions of patients globally.
Get in touch
Scientific, regulatory, physician, or partnership inquiries.
Reach the Logix Biosciences team in Monterey, California. Replies within one business day.